Head to Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) and PharmaCyte Biotech (OTCMKTS:PMCBD)

Tenaya Therapeutics (NASDAQ:TNYA) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Tenaya Therapeutics and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-86.17%	-71.14%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Earnings & Valuation

This table compares Tenaya Therapeutics and PharmaCyte Biotech”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$124.08 million	($1.44)	-0.77
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Institutional & Insider Ownership

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 32.8% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Tenaya Therapeutics and PharmaCyte Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	0	0	6	0	3.00
PharmaCyte Biotech	0	0	0	0	0.00

Tenaya Therapeutics currently has a consensus target price of $17.33, suggesting a potential upside of 1,461.56%. Given Tenaya Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tenaya Therapeutics is more favorable than PharmaCyte Biotech.

Risk & Volatility

Tenaya Therapeutics has a beta of 2.84, meaning that its stock price is 184% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500.

Summary

Tenaya Therapeutics beats PharmaCyte Biotech on 6 of the 9 factors compared between the two stocks.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.